European Leukemia Trial Registry

More Details
Title Dosefinding of Ruxolitinib with PMF, PPV-MF or PET-MF patients
Scientific Title Study of the JAK Inhibitor Ruxolitinib administered orally to patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)(CINC424A2201)
Short Title EXPAND
Trialgroup NN
Type of Trial multicentric, open-label
Disease Myeloproliferative disease(MPD) Myelofibrosis
Age >= 18 years
Status Active
Start of Recruitment 01.01.2014
Shortprotocol Shortprotocol
created 17.01.2014 Hanna Ebert
changed 17.01.2014 Hanna Ebert
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | |